Loading…
← CockpitCompetitor Analysis › 7630.HK IMPACT Therapeutics, Inc. Class HOpen in the cockpit ↗

IMPACT Therapeutics, Inc. Class H7630.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum laggard 6
Mkt cap
$319M
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$7.68M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · HKDHK$8.31
1D-13.0%
1W-3.8%
1M-32.0%
3M-30.7%
6M-78.6%
YTDn/a
1Yn/a
ATR %15.9%
52w lowhigh82.7% off high

What IMPACT Therapeutics does

Employees: 89

IMPACT Therapeutics at a glance

Size IMPACT Therapeutics (7630.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $319M, the 866th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$8.31 on 18 Nov 2026.

Performance Over six months the shares fell 78.6%, against -24.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 394.9% over the last twelve months (peer median +5.7%); the operating margin is -173.2% (peer median -186.4%).

Valuation It trades at 9.5× enterprise value to sales against a peer median of 5.3× (7th most expensive of 15).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 707630.HK 22
Six months, rebased to 100: IMPACT Therapeutics against the median of its 20 peers (local-currency closes).

IMPACT Therapeutics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueHK$134MHK$41.5MHK$36.4MHK$260M
Revenue growth—+14%-86%—
Gross profitHK$117MHK$34.9MHK$27.5MHK$251M
EBITDA-HK$227M-HK$245M-HK$218M-HK$22.4M
Net income-HK$287M-HK$321M-HK$276MHK$4.06M
Free cash flow-HK$110M-HK$106M-HK$95.5MHK$23.9M
Capital expenditureHK$499,991HK$1.64MHK$1.84MHK$380,119
Total debtn/aHK$960MHK$919MHK$0

Quarterly statements and history in the cockpit →

IMPACT Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%6945PROKCCCC2105NAUT48943880LRMRGLSIGALT358570LYEL086900CRMDCTNM4760607630.HK6-month return →1-month return →
Up and to the right = strong over both horizons. IMPACT Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×PROKCCCC48943880358570LYEL4760607630.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IMPACT Therapeutics is the large dot.

IMPACT Therapeutics competitors and peer comparison

How IMPACT Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IMPACT Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure7630.HKPeer medianRank in peer set
1-month return-32.0%-4.7%2nd lowest of 20
6-month return-78.6%-24.7%lowest of 20
Distance from 52-week high-82.7%-52.1%lowest of 20
Revenue growth (TTM)+394.9%+5.7%2nd highest of 13
Operating margin-173.2%-186.4%8th highest of 15
EV / Sales9.5×5.3×7th most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are IMPACT Therapeutics's closest peers?
The cockpit's peer set: AP Biosciences (6945.TWO), ProKidney (PROK), C4 Therapeutics (CCCC), Laekna (2105.HK), Nautilus Biotechnolgy (NAUT), Cuorips (4894.T), Medtide (3880.HK), X4 Pharmaceuticals (XFOR).
Is IMPACT Therapeutics expensive compared with its peers?
On ev / sales it trades at 9.5× against a peer median of 5.3×, 7th most expensive of 15 in its peer set.
How has IMPACT Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -78.6% against -24.7% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.